- Conditions
- Thrombosis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2041
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Institution Directory
Clinical trials at NIH Clinical Center
Sites in Bethesda, MD
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
775
Shown on this page
12
Current sort
Recently updated
Campus scope
NIH Clinical Center, Bethesda, MD
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 697–708 of 775 matching trials with a site at NIH Clinical Center, Bethesda, MD.
Live ClinicalTrials.gov results.
Live official records
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
NCT03872427
Site status not listed — check the official record
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
NCT04595747
Site status not listed — check the official record
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Rogaratinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Duarte, California • Irvine, California • Aurora, Colorado + 13 more
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT04458922
Site status not listed — check the official record
- Conditions
- Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
NCT05078905
Site status not listed — check the official record
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
NCT01696994
Site status not listed — check the official record
- Conditions
- Ovarian Carcinoma, Ovarian Germ Cell Tumor
- Interventions
- Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging
- Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 55 Years to 74 Years · Female only
- Enrollment
- 78,216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Screening for Lung Cancer in Older Patients (PLCO Screening Trial)
NCT01696968
Site status not listed — check the official record
- Conditions
- Lung Carcinoma
- Interventions
- Screening Questionnaire Administration, X-Ray Imaging
- Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 55 Years to 74 Years
- Enrollment
- 154,901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620
Site status not listed — check the official record
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
NCT01696981
Site status not listed — check the official record
- Conditions
- Colon Carcinoma, Rectal Carcinoma
- Interventions
- Screening Questionnaire Administration, Sigmoidoscopy
- Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 55 Years to 74 Years
- Enrollment
- 154,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
NCT00002540
Site status not listed — check the official record
- Conditions
- Prostate Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire Administration
- Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 55 Years to 74 Years · Male only
- Enrollment
- 76,685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
NCT06998134
Status at this site: Recruiting
- Conditions
- Muscle Weakness, Problems Moving Their Arms and Legs
- Interventions
- Extension assist knee ankle foot orthosis (EA-KAFO)
- Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation
NCT07516379
Status at this site: Recruiting
- Conditions
- Lung Transplant, End Stage Lung Disease, Rejection
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
About this NIH Clinical Center institution page
- What this page lists
- ClinicalTrials.gov records that list NIH Clinical Center in Bethesda, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, browse by condition, or browse by U.S. city.